#Norway #Oslo #Radspherin #Ovarian Cancer #Oncoinvent

Oncoinvent's Phase 1 Trial Results

Oncoinvent ASA, a Norwegian clinical-stage radiopharmaceutical company, has recently unveiled promising final data from its Phase 1 clinical trial (RAD-18-001) assessing Radspherin® for the treatment of ovarian cancer. This trial specifically focused on patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis.

Purpose and Approach

Radspherin® aims to directly target micro-metastases within the peritoneum following surgery, thus preventing or delaying recurrence. The treatment employs radium-224, an alpha-emitter, to eliminate hidden cancer cells that may lead to new tumor growth.

Trial Overview

In the Phase 1 trial, a total of 21 patients participated, with 10 receiving the highest recommended intraperitoneal dose of 7 MBq after a cautiously escalated dosage. The results of a 24-month follow-up showed only one patient experiencing peritoneal recurrence among those treated with Radspherin®, maintaining a peritoneal recurrence rate of just 10%.

To place this in perspective, roughly 55-60% of patients undergoing the best-standard care would typically expect a recurrence at the 24-month mark, highlighting the efficacy of Radspherin®. Total recurrence rates—including those with lymph node metastases—stood at 30%, which further emphasizes the treatment's potential.

Leadership Insights

Oystein Soug, CEO of Oncoinvent, expressed his excitement about these results, stating: "These highly encouraging results conclude our Phase 1 program for Radspherin® and fuel our determination to advance Radspherin® as an innovative treatment for patients with peritoneal metastases as quickly as possible." His gratitude extended to patients, investigators, and the Oncoinvent team for their invaluable contributions.

Dr. Luis Chiva, Principal Investigator and Director of the Department of Obstetrics and Gynecology at the Clinica Universidad de Navarra in Spain, further elaborated, mentioning that these findings offer hope that Radspherin® can significantly delay disease progression and increase the likelihood of longer and healthier lives for patients. He noted the encouraging aspect that new recurrences occurred mainly in lymph nodes, which are often associated with a more favorable survival outlook than peritoneal recurrences.

Future Prospects

The ongoing commitment to furthering research into Radspherin® remains a priority for Oncoinvent. The company is currently advancing its clinical development through a Phase 2 trial and is eager to release interim results in the following year.

The RAD-18-001 trial, which has been conducted across various sites in Norway, Belgium, and Spain, primarily focused on understanding the dosing, safety, tolerability, and potential efficacy of intraperitoneal administration of Radspherin® following surgical resection.

With a team of about 40 professionals and a state-of-the-art facility in Nydalen, Oslo, Oncoinvent continues to innovate in the field of cancer treatment through their research and development of novel radiopharmaceutical therapies. Radspherin®, in particular, stands out as a promising solution that aims to tackle the challenges posed by peritoneal metastases in ovarian cancer, signaling a potential new direction in cancer treatment strategies. The results from this Phase 1 trial pave the way for continued exploration and optimism concerning Radspherin®'s role in future oncology treatments.

Conclusion

Oncoinvent's positive final data presents a ray of hope in the fight against ovarian cancer. As they progress through clinical trials, stakeholders in the medical community look forward to the impact that Radspherin® could have on patient care and outcomes, aiming for a future where treatment options are both effective and accessible.